A serum level of IGF-I, IGF-II and IGFBP-3 in patients with small cell lung cancer (SCLC) during chemotherapy Source: Eur Respir J 2006; 28: Suppl. 50, 86s Year: 2006
Serum level of IGF-I and IGF-II in patients with non-small cell lung cancer (NSCLC) during chemotherapy Source: Eur Respir J 2004; 24: Suppl. 48, 82s Year: 2004
IGF-I and IGFBP-3 concentrations in the blood serum and lung cancer risk Source: Annual Congress 2007 - Biology of thoracic malignancies Year: 2007
Serum levels of interleukin 8 and plasma levels of osteopontin in patients with non-small cell lung cancer during chemotherapy Source: Annual Congress 2011 - Instructive clinical aspects of lung cancer Year: 2011
Serum level of GFBP-1 and IGFBP-6 in patients with non-small cell lung cancer (NSCLC) during chemotherapy Source: Annual Congress 2009 - Biological and clinical markers in lung cancer Year: 2009
Serum levels of sFas and sFasL during chemotherapy of lung cancer Source: Eur Respir J 2005; 26: Suppl. 49, 329s Year: 2005
Prognostic value of il-6 and TNF-alfa serum concentration in advanced non-small lung cancer patients Source: Eur Respir J 2003; 22: Suppl. 45, 251s Year: 2003
Increased serum levels of IL-18 are associated with lower survival and bone metastasis in non-small-cell lung cancer Source: Annual Congress 2008 - Biology and prognosis in thoracic oncology Year: 2008
Serum levels of TGFβ and VEGF in lung cancer patients and healthy subjects Source: Eur Respir J 2004; 24: Suppl. 48, 43s Year: 2004
Evaluation of serum levels of Sirtuin-1 in lung cancer patients Source: Virtual Congress 2020 – Prognostic and predictive factors: treatment of lung cancer Year: 2020
Clinical significance of serum survivin, MGB-1 and Pref-1 levels during chemotherapy of lung cancer Source: Annual Congress 2009 - Biological and clinical markers in lung cancer Year: 2009
Serum tumor markers in lung cancer patients Source: Annual Congress 2007 - Biology, diagnosis and rare tumours in thoracic malignancies Year: 2007
CEA levels in the serum and induced sputum of lung cancer patients Source: Eur Respir J 2005; 26: Suppl. 49, 324s Year: 2005
Plasma leptin levels in nonsmall cell lung carcinoma (NSCLC) patients at the time of the diagnosis Source: Eur Respir J 2001; 18: Suppl. 33, 65s Year: 2001
Serum level of interleukin-6 as a prognostic factor in advanced nonsmall-cell lung cancer Source: Eur Respir J 2003; 22: Suppl. 45, 250s Year: 2003
Relation between bone metastasis in lung cancer and serum IL-6 levels Source: Annual Congress 2008 - Various aspects of thoracic oncology Year: 2008
Serum levels of STR-3 and TIMP-2 in lung cancer Source: Eur Respir J 2002; 20: Suppl. 38, 230s Year: 2002
Elevated serum levels of interleukin-8 in advanced non-small cell lung cancer patients: Relationship with prognosis Source: Annual Congress 2010 - Biomarkers for lung cancer Year: 2010
Clinical significance of serum adipokines levels in lung cancer Source: Annual Congress 2009 - Biological and clinical markers in lung cancer Year: 2009
Serum C-reactive protein and procalcitonin levels in non-small cell lung cancer patients Source: Annual Congress 2012 - Instructive clinical aspects of thoracic oncology Year: 2012